REFINE
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE). Click here to learn more.
- Clinical Trials
- Biliary Tract Cancer
- Myelofibrosis
- Bladder Cancer
- Colorectal Cancer
- Paroxysmal Nocturnal Hemoglobulinuria
- Clinical Trials at UCBC
- Breast Cancer
- Esophageal Cancer
- Gastric Tumors
- Head & Neck Cancer
- Kidney Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Neuroendocrine Tumors
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Sarcoma Tumors
- Brain & Spinal Cord Tumors
- Solid Tumors
